

## Bringing liquid biopsy to early detection of cancer - Nucleix' journey

Aharona Shuali

- o Executive Summary Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients.

- o Core Technology Nucleix has developed its proprietary EpiCheck technology for the ultrasensitive detection of DNA methylation. The EpiCheck technology utilizes a novel approach to process cell free DNA, which results in extraordinary low background noise levels. This enables the detection of minimal amounts of DNA methylation to be detected by standard readout approaches such as PCR or next generation sequencing. The Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The EpiCheck technology enables a novel approach to marker discovery, which Nucleix has leveraged in its unparalleled Lung-Atlas program. The combination of this ultrasensitive detection method and the comprehensive marker discovery effort led to the development of a novel assay for early lung cancer detection. The Company's non-invasive EpiCheck® delivers highly accurate and sensitive results, while providing a seamless testing option for physicians, patients, and the healthcare system.

- o Product Profile The Company is building an EpiCheck® franchise in lung cancer and in bladder cancer. The Company's first commercial product, Bladder EpiCheck® kit is FDA cleared and CE-marked and available in Europe and Israel for primary and recurrent bladder and upper tract urinary cancers and in the USA for recurrent bladder cancer. Furthermore, Nucleix has built the world's most comprehensive DNA methylation map (Lung-ATLAS) for plasma derived cfDNA. This Lung-ATLAS has served as the foundation for the development of a screening test for high-risk individuals, Lung EpiCheck. Initial results from a large multicenter study for Lung EpiCheck®, have recently been presented and showed excellent early-stage sensitivity (87% in stage I NSCLC).

- o Business Strategy The company is selling the Bladder EpiCheck® kit in Europe the USA. The company is also advancing a Lung EpiCheck® in a dual strategy. The test will be available centralized through its San Diego based CLIA-certified CAP accredited lab. Furthermore, the Company aims to develop a distributable version of Lung EpiCheck. o What's Next? Nucleix is currently running large scale studies aimed to validate the initial excellent results for Lung EpiCheck.